SciClone Pharmaceuticals Inc is a Delaware corporation was incorporated in 1990. The Company is a specialty pharmaceutical company with a substantial commercial business and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders. The Company's primary product, ZADAXIN (thymalfasin) is approved in over 30 countries and may be used for the treatment of HBV, HCV, and certain cancers, and as a vaccine adjuvant according to the local regulatory approvals. It markets approximately 7 partnered and in-licensed products in China, including Aggrastat, an interventional cardiology product. The Company operates is two segments based on the nature and locations of its customers: China and the rest of the world which includes its US and Hong Kong operations. The Company sells ZADAXIN in various international markets through its wholly owned subsidiary, SciClone Pharmaceuticals International Ltd. SPIL orders ZADAXIN from its European manufacturer and contracts with a third party for the storage of its finished goods inventory at warehousing facilities in Hong Kong. SPIL then distributes its product from these warehousing facilities based on purchase orders from its customers. ZADAXIN is manufactured in Europe by third parties under exclusive contract manufacturing and supply agreements. Its competitors include pharmaceutical companies, biotechnology firms, universities and other research institutions, in the US, China and other territories, that are actively engaged in research and development or marketing of products in the therapeutic areas the Company is pursuing. The Company's products in clinical development in the US, China and other foreign countries are subject to approval by the FDA, the SFDA and similar regulatory authorities.